Detalhe da pesquisa
1.
ERß-Dependent Direct Suppression of Human and Murine Th17 Cells and Treatment of Established Central Nervous System Autoimmunity by a Neurosteroid.
J Immunol
; 197(7): 2598-609, 2016 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27549171
2.
Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens.
Int J Mol Sci
; 17(9)2016 Aug 25.
Artigo
Inglês
| MEDLINE | ID: mdl-27571060
3.
Role of anthropometric characteristics in idiopathic carpal tunnel syndrome.
Arch Phys Med Rehabil
; 94(4): 737-44, 2013 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-23178273
4.
Low vitamin D levels in healthy controls and patients with autoimmune neuromuscular disorders in Greece.
Acta Neurol Belg
; 116(1): 57-63, 2016 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-26183131
5.
The possible effects of the solar and geomagnetic activity on multiple sclerosis.
Clin Neurol Neurosurg
; 146: 82-9, 2016 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-27161905
6.
Trigeminal herpes zoster complicated by Ramsay Hunt syndrome.
Neurologist
; 19(2): 38-9, 2015 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-25607330
7.
Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation.
PLoS One
; 10(8): e0135434, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-26317430
8.
Properties of myelin altered peptide ligand cyclo(87-99)(Ala91,Ala96)MBP87-99 render it a promising drug lead for immunotherapy of multiple sclerosis.
Eur J Med Chem
; 101: 13-23, 2015 Aug 28.
Artigo
Inglês
| MEDLINE | ID: mdl-26112377
9.
Cytokines as Biomarkers of Treatment Response to IFN ß in Relapsing-Remitting Multiple Sclerosis.
Mult Scler Int
; 2014: 436764, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-25152817
10.
Correction: Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation.
PLoS One
; 11(3): e0151411, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-26963810
11.
Remitting-relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab.
Int J Gen Med
; 3: 313-20, 2010 Oct 05.
Artigo
Inglês
| MEDLINE | ID: mdl-21042570